表紙:FLUAD四価医薬品の考察と市場予測 - 2032年
市場調査レポート
商品コード
1381085

FLUAD四価医薬品の考察と市場予測 - 2032年

FLUAD QUADRIVALENT Drug Insight and Market Forecast - 2032

出版日: | 発行: DelveInsight | ページ情報: 英文 30 Pages | 納期: 1~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.46円
FLUAD四価医薬品の考察と市場予測 - 2032年
出版日: 2023年11月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 1~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、主要6市場(米国、ドイツ、フランス、イタリア、スペイン、英国)におけるFLUAD四価ワクチンについて調査分析し、作用機序、用法と用量、研究開発活動に関する考察や、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 季節性インフルエンザにおけるFLUAD四価の概要

  • 製品の詳細
  • 臨床開発
    • 臨床研究
    • 臨床試験情報
    • 安全性と有効性
  • 規制上のマイルストーン
  • その他の開発活動
  • 製品のプロファイル

第3章 競合情勢(上市済みの治療法)

第4章 競合情勢(後期の新治療法)

第5章 FLUAD四価市場の評価

  • 季節性インフルエンザにおけるFLUAD四価の市場見通し
  • 主要6市場の分析
    • 主要6市場の季節性インフルエンザ向けFLUAD四価の市場規模
  • 市場の分析:国別
    • 米国の季節性インフルエンザ向けFLUAD四価の市場規模
    • ドイツの季節性インフルエンザ向けFLUAD四価の市場規模
    • 英国の季節性インフルエンザ向けFLUAD四価の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

図表

List of Tables

  • Table 1: FLUAD QUADRIVALENT, Clinical Trial Description, 2023
  • Table 2: FLUAD QUADRIVALENT, General Description
  • Table 3: Competitive Landscape (Marketed Therapies)
  • Table 4: Competitive Landscape (Emerging Therapies)
  • Table 5: FLUAD QUADRIVALENT Market Size in the 6MM, in USD million (2019-2032)
  • Table 6: FLUAD QUADRIVALENT Market Size in the US, in USD million (2019-2032)
  • Table 7: FLUAD QUADRIVALENT Market Size in Germany, in USD million (2019-2032)
  • Table 8: FLUAD QUADRIVALENT Market Size in France, in USD million (2019-2032)
  • Table 9: FLUAD QUADRIVALENT Market Size in Italy, in USD million (2019-2032)
  • Table 10: FLUAD QUADRIVALENT Market Size in Spain, in USD million (2019-2032)
  • Table 11: FLUAD QUADRIVALENT Market Size in the UK, in USD million (2019-2032)

List of Figures

  • Figure 1: FLUAD QUADRIVALENT Market Size in the 6MM, USD million (2019-2032)
  • Figure 2: FLUAD QUADRIVALENT Market Size in the United States, USD million (2019-2032)
  • Figure 3: FLUAD QUADRIVALENT Market Size in Germany, USD million (2019-2032)
  • Figure 4: FLUAD QUADRIVALENT Market Size in France, USD million (2019-2032)
  • Figure 5: FLUAD QUADRIVALENT Market Size in Italy, USD million (2019-2032)
  • Figure 6: FLUAD QUADRIVALENT Market Size in Spain, USD million (2019-2032)
  • Figure 7: FLUAD QUADRIVALENT Market Size in the United Kingdom, USD million (2019-2032)
目次
Product Code: DIDM1060

“"FLUAD QUADRIVALENT Drug Insight and Market Forecast - 2032" report provides comprehensive insights about FLUAD QUADRIVALENT for seasonal influenza in the six major markets. A detailed picture of the FLUAD QUADRIVALENT for seasonal influenza in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the FLUAD QUADRIVALENT for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FLUAD QUADRIVALENT market forecast analysis for seasonal influenza in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.

Drug Summary:

FLUAD QUADRIVALENT (influenza vaccine, adjuvanted), a sterile injectable emulsion for intramuscular use, is a quadrivalent, inactivated influenza vaccine prepared from a virus propagated in the allantoic cavity of embryonated hens' eggs inoculated with a specific type of influenza virus. FLUAD QUADRIVALENT is prepared by combining the four virus antigens with the MF59C.1 adjuvant. After combining, FLUAD QUADRIVALENT is a sterile, milky-white injectable emulsion supplied in single-dose prefilled syringes containing 0.5 mL dose. Each 0.5 mL dose contains 15 mcg of hemagglutinin from each of the four recommended influenza strains and MF59C.1 adjuvant (9.75 mg squalene, 1.175 mg of polysorbate 80, 1.175 mg of sorbitan trioleate, and 0.66 mg of sodium citrate dihydrate and 0.04 mg of citric acid monohydrate) at pH 6.9-7.7.

  • Dosage and administration
  • A single 0.5 mL dose for intramuscular injection
  • Dosage forms and strengths
  • Injectable emulsion supplied in 0.5 mL single-dose prefilled syringes

Scope of the Report:

The report provides insights into:

  • A comprehensive product overview including the FLUAD QUADRIVALENT description, mechanism of action, dosage and administration, research and development activities in seasonal influenza.
  • Elaborated details on FLUAD QUADRIVALENT regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the FLUAD QUADRIVALENT research and development activities in seasonal influenza across the United States and Europe.
  • The report also covers the patents information with expiry timeline around FLUAD QUADRIVALENT.
  • The report contains forecasted sales of FLUAD QUADRIVALENT for seasonal influenza till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for seasonal influenza.
  • The report also features the SWOT analysis with analyst views for FLUAD QUADRIVALENT in seasonal influenza.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FLUAD QUADRIVALENT Analytical Perspective by DelveInsight

In-depth FLUAD QUADRIVALENT Market Assessment

This report provides a detailed market assessment of FLUAD QUADRIVALENT for seasonal influenza in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2023 to 2032.

FLUAD QUADRIVALENT Clinical Assessment

The report provides the clinical trials information of FLUAD QUADRIVALENT for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

  • In the coming years, the market scenario for seasonal influenza is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FLUAD QUADRIVALENT dominance.
  • Other emerging products for seasonal influenza are expected to give tough market competition to FLUAD QUADRIVALENT and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FLUAD QUADRIVALENT in seasonal influenza.
  • Our in-depth analysis of the forecasted sales data of FLUAD QUADRIVALENT from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FLUAD QUADRIVALENT in seasonal influenza.

Key Questions:

  • What is the product type, route of administration and mechanism of action of FLUAD QUADRIVALENT?
  • What is the clinical trial status of the study related to FLUAD QUADRIVALENT in seasonal influenza and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FLUAD QUADRIVALENT development?
  • What are the key designations that have been granted to FLUAD QUADRIVALENT for seasonal influenza?
  • What is the forecasted market scenario of FLUAD QUADRIVALENT for seasonal influenza?
  • What are the forecasted sales of FLUAD QUADRIVALENT in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom?
  • What are the other emerging products available and how are these giving competition to FLUAD QUADRIVALENT for seasonal influenza?
  • Which are the late-stage emerging therapies under development for the treatment of seasonal influenza?

Table of Contents

1. Report Introduction

2. FLUAD QUADRIVALENT Overview in seasonal influenza

  • 2.1. Product Detail
  • 2.2. Clinical Development
    • 2.2.1. Clinical studies
    • 2.2.2. Clinical trials information
    • 2.2.3. Safety and efficacy
  • 2.3. Regulatory Milestone
  • 2.4. Other Developmental Activities
  • 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. FLUAD QUADRIVALENT Market Assessment

  • 5.1. Market Outlook of FLUAD QUADRIVALENT in seasonal influenza
  • 5.2. 6MM Analysis
    • 5.2.1. Market Size of FLUAD QUADRIVALENT in the 6MM for seasonal influenza
  • 5.3. Country-wise Market Analysis
    • 5.3.1. Market Size of FLUAD QUADRIVALENT in the United States for seasonal influenza
    • 5.3.2. Market Size of FLUAD QUADRIVALENT in Germany for seasonal influenza
    • 5.3.3. Market Size of FLUAD QUADRIVALENT in France for seasonal influenza
    • 5.3.4. Market Size of FLUAD QUADRIVALENT in Italy for seasonal influenza
    • 5.3.5. Market Size of FLUAD QUADRIVALENT in Spain for seasonal influenza
    • 5.3.6. Market Size of FLUAD QUADRIVALENT in the United Kingdom for seasonal influenza

6. SWOT Analysis

7. Analysts' Views

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options